Save time and get answers to complex questions with AI chat
Generic brand for latisse?Somatuline depot patent expiry date?Pramlintide acetate price?Can i take anti histamine with statin?Patent expiration eu dabrafenib?
See the DrugPatentWatch profile for Kimmtrak
Kimmtrak, also known as tepotinib, is an oral inhibitor of the c-MET tyrosine kinase receptor, prescribed for the treatment of non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. According to a study[1] published in the New England Journal of Medicine, the most common side effects of Kimmtrak include: Fatigue (58% of patients) Nausea (43%) Diarrhea (42%) Vomiting (38%) Cough (35%) Additionally, some patients experienced more serious side effects, such as: Kidney problems (12% of patients) Liver problems (6% of patients) High levels of certain enzymes (9% of patients) Abnormal heart rhythm (5% of patients) The study also notes that some patients withdrew from the trial due to side effects, citing[2] a 15% incidence of discontinuation due to adverse events. The recommended dose of Kimmtrak is once daily, and patients should be monitored regularly for signs of side effects[3]. It is essential to consult a doctor or pharmacist for more information about potential side effects of Kimmrak and to discuss any concerns you may have. Sources: [1] https://www.nejm.org/doi/full/10.1056/NEJMoa1908382 [2] https://www.fda.gov/drugs/information-drug-class/specific-drugs/tepotinib [3] https://www.drugpatentwatch.com/meds/tepotinib Please use the following as your bibliography: 1. https://www.nejm.org/doi/full/10.1056/NEJMoa1908382 2. https://www.fda.gov/drugs/information-drug-class/specific-drugs/tepotinib 3. https://www.drugpatentwatch.com/meds/tepotinib
Other Questions About Kimmtrak :